Sparreboom A - Search Results

1

Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.

Sparreboom A, Chen H, Acharya MR, Senderowicz AM, Messmann RA, Kuwabara T, Venzon DJ, Murgo AJ, Headlee D, Sausville EA, Figg WD. Sparreboom A, et al. Clin Cancer Res. 2004 Oct 15;10(20):6840-6. doi: 10.1158/1078-0432.CCR-04-0805. Clin Cancer Res. 2004. PMID: 15501960 Clinical Trial.

2

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Sparreboom A, et al. Cancer Res. 1996 May 1;56(9):2112-5. Cancer Res. 1996. PMID: 8616858

3

Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.

Sparreboom A, de Jonge MJ, Punt CJ, Nooter K, Loos WJ, Porro MG, Verweij J. Sparreboom A, et al. Clin Cancer Res. 1998 Aug;4(8):1915-9. Clin Cancer Res. 1998. PMID: 9717819 Clinical Trial.

4

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L. Sparreboom A, et al. Clin Cancer Res. 1998 Aug;4(8):1937-42. Clin Cancer Res. 1998. PMID: 9717822

5

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J. Sparreboom A, et al. Cancer Res. 1999 Apr 1;59(7):1454-7. Cancer Res. 1999. PMID: 10197613

6

Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.

de Jonge MJ, Verweij J, Planting AS, van der Burg ME, Stoter G, de Boer-Dennert MM, de Bruijn P, Brouwer E, Vernillet L, Sparreboom A. de Jonge MJ, et al. Among authors: sparreboom a. Clin Cancer Res. 1999 Aug;5(8):2012-7. Clin Cancer Res. 1999. PMID: 10473080 Clinical Trial.

7

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A. van Tellingen O, et al. Among authors: sparreboom a. Clin Cancer Res. 1999 Oct;5(10):2918-24. Clin Cancer Res. 1999. PMID: 10537361

8

Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.

Eskens FA, Levitt NC, Sparreboom A, Choi L, Mather R, Verweij J, Harris AL. Eskens FA, et al. Among authors: sparreboom a. Clin Cancer Res. 2000 Feb;6(2):431-3. Clin Cancer Res. 2000. PMID: 10690520 Clinical Trial.

9

Topotecan lacks third space sequestration.

Gelderblom H, Loos WJ, Verweij J, de Jonge MJ, Sparreboom A. Gelderblom H, et al. Among authors: sparreboom a. Clin Cancer Res. 2000 Apr;6(4):1288-92. Clin Cancer Res. 2000. PMID: 10778953 Clinical Trial.

10

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J. van Zuylen L, et al. Among authors: sparreboom a. Clin Cancer Res. 2000 Apr;6(4):1365-71. Clin Cancer Res. 2000. PMID: 10778964 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters